Last reviewed · How we verify
DTPa-HBV-IPV (Infanrix penta™)
DTPa-HBV-IPV is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis.
DTPa-HBV-IPV is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis. Used for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis in infants and children.
At a glance
| Generic name | DTPa-HBV-IPV (Infanrix penta™) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease Prevention |
| Phase | Phase 3 |
Mechanism of action
This pentavalent vaccine contains inactivated toxoids (diphtheria and tetanus), acellular pertussis antigens, recombinant hepatitis B surface antigen, and inactivated poliovirus particles. Upon intramuscular injection, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory B cells against all five pathogens. This provides immunization against these five serious infectious diseases in a single formulation.
Approved indications
- Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis in infants and children
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability
- Drowsiness
- Loss of appetite
Key clinical trials
- Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines (PHASE3)
- Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children (PHASE4)
- Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately (PHASE3)
- Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTPa-HBV-IPV (Infanrix penta™) CI brief — competitive landscape report
- DTPa-HBV-IPV (Infanrix penta™) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI